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Abstract: Lupus anticoagulant (LA) and anticardiolipin antibodies (ACAs) are acquired
antiphospholipid antibodies (APAs), which are
considered to be important markers for
pregnancy losses and intrauterine fetal
demise. LA and ACAs have anticoagulant
effects in vitro and thrombotic effects in vivo
and are considered to be the cause of recurrent pregnancy losses (RPLs), resulting from
placental vascular thrombosis and infarction.
The aim of this study was to identify the
most sensitive and specific method of determining APA positivity and to evaluate the
prevalence of APA in patients with unexplained RPL.
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The experiment consisted of 25 women with
unexplained RPL, the patient group, and 15
healthy women with successful pregnancies,
the control group. ACA positivity was determined with ELISA and LA activity with phospholipid dependent coagulation tests
(PDCTs): prothrombin time (PT), activated

Introduction
Lupus anticoagulant (LA) and anticardiolipin
antibodies (ACAs) are acquired antiphospholipid
antibodies (APAs) characteristically found in patients with
SLE or related autoimmune diseases and considered to be
important markers for pregnancy losses and intrauterine
fetal demise (1, 2).
LA is an antibody (IgG and/or IgM) that prolongs
phospholipid dependent coagulation tests (PDCTs) by
binding to epitopes on the phospholipid portion of
prothrombinase (a complex of FXa, FVa, PL and Ca+2 ) (35). Closely related to LA, ACAs are antiphospholipid
autoantibodies (IgG, IgM and IgA) which have specificity
for negatively charged phospholipids such as cardiolipin
and are detected by immunoassays that use cardiolipin as
the solid phase (1, 6, 7). It has been suggested recently
that LA and ACAs form two distinct but related subgroups
(8, 9).

partial thromboplastin time (APTT), kaolin
clotting time (KCT) and a platelet neutralization procedure (PNP).
LA activity was detected in 5 of the 25
women in the experimental group (20%),
but in none of the 15 women in the control
group Increased ACA levels were observed in
8 of the experimental group (32%) and in
one of the control group subjects (7%).
These results provide quantitative evidence of
the association between APA and RPL. LA
was best identified through KCT and should
be specifically confirmed by PNP. Screening
for APAs, both with ACAs for sensitivity and
LA for specificity, is indicated in patients with
adverse pregnancy outcomes.
Key Words: Lupus anticoagulant (LA), anticardiolipin antibodies (ACAs), antiphospholipid antibodies (APAs), pregnancy losses.

APAs are found in different clinical situations, such as
autoimmune diseases (including SLE and rheumatoid
artritis), infections (including syphilis and AIDS),
malignancy and drug exposure (chlor promazine,
procainamide, phenothiazines, hydralazine, quinidine,
dilantin, etc.) (1, 7, 10-18). APAs are also sometimes
found in healthy people (2).
In recent years, it has been suggested that LA and
ACAs are strongly associated with a diverse set of clinical
manifestations, including venous and arterial thrombosis,
neuropsychiatric disorders, thrombocytopenia and RPL,
which together constitute the APA syndrome (2, 4, 10,
19-21). It is thought that patients who have LA or ACAs
have a greater risk of developing these complications and
that these associations are largely independent of the
underlying disease (2, 5, 22).
Recently, LA and ACAs have been recognized as having
a role in RPL, even in women with no clinically diagnosed
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autoimmune disease (3). LA and ACAs having
anticoagulant effects in vitro and thrombotic effects in
vivo (23) are considered to be the cause of RPL, resulting
from placental vascular thrombosis and infarction (1, 2,
4, 24).
The association between APAs and RPL is well
established (25, 26). What is still unclear is the actual
prevalence of APAs in women with unexplained RPL. The
aim of this study was to identify the most sensitive and
specific method of determining APA positivity and to
evaluate the prevalence of APAs in patients with
unexplained RPL.
Materials & Methods
Materials: A case-control study of the association
between RPL, LA and ACAs was conducted in the hospital
of Ege University School of Medicine. The experimental
subjects were 25 women (median age 30 years, range
19-41) with no clinical or laboratory evidence of SLE or
related autoimmune diseases, and whose only
pregnancies had resulted in two or more consecutive
unexplained spontaneous or missed abortions or IUMF.
The control group consisted of 15 women (median age
34, range 26-49) who had had one or more normal
pregnancies without previous spontaneous abortion.
These women were admitted to the same hospital for
acute conditions that were not immunologic, infective,
neoplastic, gynecologic or cardiovascular. In the patient
group the following parameters were screened in order
to detect immunologic etiology and to exclude the
endocrine, metabolic, anatomic, infectious and genetic
factors that can lead to RPL:
– Normal standard medical and gynecologic
examination.
– Hysterosalpingogram (HSG), ultrasonogram (US),
luteal phase endometrial biopsy.
– Hormonal profile (FSH, LH, progesterone,
oestradiol, prolactin, free testosterone, TSH, T3, T4)
– Biochemical profile (including oral glucose tolerance
test (OGTT), protein electrophoresis, urine analysis,
haemogram, blood grouping, thrombocyte count).
– TORCH group tests, Group Agglutination tests,
hepatitis markers, VDRL, TPHA, RPR, ICT.

Based on these data, cases with known etiology such
as SLE were excluded from the study. All the experimental
cases and controls were tested for LA and ACAs.
Methods used in APA determination: ACA values
were determined using an ELISA test (AsserachromR APA,
Diagnostica Stago). LA activity was determined through
PDCTs: prothrombin time (PT), Neoplastine Ca 12
(Diagnostica Stago); activated partial thromboplastin time
(APTT), Activated Thrombofax (Ortho Diagnostic
Systems); kaolin clotting time (KCT), using Exner’s
method (27), and also with a commercial kit of kaolin;
APTT (C.K.Prest, Diagnostica Stago); and a platelet
neutralization procedure (PNP), using the method of
Triplett et al. (18).
We prepared platelet poor plasma (PPP) and looked
for any prolongation in the PDCT. In order to determine
ACAs and PDCT (not including KCT), after ruling out
recent heparin treatment, we collected blood on
trisodium citrate (9 parts blood to 1 part 0.109 M
trisodium citrate as the anticoagulant) and centrifuged at
2500 g for 15 minutes at 20˚C to obtain PPP, which was
stored at -20˚C until use. Blood for the KCT tests, using
Exner’s method (27), was collected through venipuncture
into polyethylene tubes containing one-tenth (final) 3.8%
w/v sodium citrate pH 6.5. Pooled PPP from 20 normal
individuals was prepared for use in mixing tests.
PDCTs were considered positive when the ratio of the
subject clotting time to the mean of the control clotting
time exceeded 1:3 (baseline test) and when this ratio
remained greater than 1:2 upon 1:1 mixture of
experimental and normal PPP (performed to exclude
clotting factor deficiency). The diagnosis of the LA was
based on a prolonged PDCT not corrected with a mixing
test, together with a positive PNP result (baseline test +
mixing test + PNP) (7, 18).
In determining ACAs, the positive control, the
negative control and the cutoff (included in the ready-touse kit) by comparison enabled a semi-quantitative
evaluation. The results were considered positive when the
resultant OD readings at 492 nm on a Titertek Multiscan
were above the cutoff value and negative when the OD
values were below the cutoff value.
Statistical analysis: The significance of the difference
between the mean values of the parameters were
evaluated using the Mann-Whitney non-parametric test.

– IgG, IgA, IgM, C3, C4, ANA, Anti-DNA Ab, LE cells,
CRP, Latex, Antisperm Ab.
– Maternal and paternal karyotype determination
from peripheral leucocytes.
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Results
LA activity was detected in 5 of the 25 experimental
subjects (20%), but in none of the 15 controls. Increased
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Table 1.

ACA and PDCT Results of APA (+) Experimental and Control Groups.

APA (+)
Experimental

ACA

ACA

PT

APTT*

APTT**

KCT*

KCT**

CK.P*

CK.P**

PNP

SC

LA

+

OD492

1

229

+

18”

33”

30”

120”

120”

65”

51”

39”

53”

2

209

+

13”

27”

-

100”

85”

35”

35”

-

-

-

3

170

+

13”

32”

28”

85”

90”

47”

58”

37”

49”

+

4

382

+

14”

32”

28”

150”

145”

50”

50”

39”

52”

+

5

513

++

14”

36”

37”

200”

180”

60”

65”

32”

60”

+

6

1809

++

15”

37”

36”

130”

125”

41”

39”

37”

41”

+

7

183

+

13”

27”

-

65”

65”

30”

30”

-

-

-

8

357

++

14”

28”

-

110”

100”

35”

35”

-

-

-

Control

178

+

13”

27”

-

90”

90”

35”

35”

-

-

-

APA Cutoff: OD492=151, APA (+): OD492= 152-300, APA (++): OD492 ≥ 301, LA (+): PNP ≤ 39”, LA (-): PNP > 39”
*Baseline Test, **Mixing Test, SC: Saline Control

ACA levels were observed in 8 of the 25 subjects (32%)
and in one of the 15 controls (7%).
The ACA and PDCT results of the APA (+)
experimental and control groups are presented in Table 1.
Table 2 shows the mean±SEM values of each method
used in APA determination (ACA, KCT, CK.P, APTT and
PT).
Table 3 shows the significance of the difference
between the mean values of the parameters (MannWhitney non-parametric test) in the control and the
experimental groups.
Discussion
In the general population, the prevalence of LA and
ACAs ranges from 0% to 2% and 7.5%, respectively (2,
3, 20, 22, 28-31). In reports relating to APA prevalence
in RPL cases with no apparent etiology, a prevalence of 348% is stated for LA and 8-50% for ACA (2, 3, 7, 19,
25, 32). The results of 16 studies of 827 RPL cases show
that the frequency of APA positivity is 29% (25% for LA
and 37% for ACAs) (7). This wide range of prevalence
values is probably due to the use of different criteria in
patient selection, different methods used in determining
APA and the lack of international uniformity for the
definition of the LA. PDCTs used to determine LA vary
widely in sensitivity (7, 32, 33). Methods of determining
ACAs vary according to antibody subclass or class and
cutoff values used for positivity (2, 7, 25).

In this study, LA activity was detected in 5 of the 25
experimental subjects (20%), but in none of the 15
controls. Increased ACA levels were observed in 8 of the
25 experimental subjects (32%) and in one of the 15
controls (7%). These results offer quantitative evidence
of the association between APAs and RPL. While the LA
prevalence of the control group shows concordance with
the studies of El-Roeiy A (28) and Miliez J (30), the ACA
prevalence (7%) of our controls are also in concordance
with the ones of Love et al. (2) and al-Momen et al. (26).
The results (prevalence) of our RPL cases (32% ACA and
20% LA) are in concordance with the data of McNeil et al.
(7) and al-Momen et al. (26), who observed 30% APA
positivity in idiopathic RPL cases.
In spite of the fact that LA and ACAs are observed
together, it is interesting to note that in most of the
studies there is no correlation in their levels (7). In
accordance with the findings of McNeil et al. (7, 34) and
Triplett et al. (8), in our study no correlation between the
levels of ACA and LA was found (Table 1 and Table 3).
It has been well documented that APTT is a test with
low sensitivity and is insufficient for detecting weak
inhibitors (35, 36). In agreement with these data, it was
observed in this study that APTT had the lowest
sensitivity of the PDCT tests applied to determine LA
activity (Table 2).
KCT is a specific type of APTT independent of tissue
thromboplastine. It has been suggested that this is the
most sensitive test for detecting LA activity (7, 35), an
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Control G.

APA(+) EG n=8

n=15

APA(-) EG

Total EG

n=17

n=25

ACA

112±9

481±194

101±7

222±70

KCT

75±3

120±15

71±2

87±7

CK.P

33.4±0.4

45.4±4.4

33.1±05

37.0±1.8

APTT

26.9±0.1

31.5±1.4

26.6±0.2

28.2±0.6

13±0

14.3±0.6

13±0

13.4±0.2

PT

ACA

APTT

KCT

CK.P

PT

APA(+) EG-APA(-) EG

p<0.01

p<0.01

p<0.01

p<0.01

p<0.05

APA(+) EG-CG

p<0.01

p<0.01

p<0.01

p<0.05

p<0.05

APA(-) EG-CG

NS

NS

NS

NS

NS

TOTAL EG-CG

NS

NS

NS

NS

NS

Table 2.

Mean±SEM values of methods
used in APA determination

Table 3.

The significance of the difference between the mean values
of the parameters in the control (CG) and experimental
groups (EG).

(Mann-Whitney non-parametric test) p>0.05=NS:Not significant.

observation supported by many authors in recent years
(36, 37). The procedure of eliminating the inhibitor
effect by the addition of a platelet suspension, proposed
by Triplett et al. (38), is called PNP and was reported by
Kornberg et al. in 1989 to be the most specific method
for confirming the diagnosis of LA activity (7). Similarly,
we also observed that LA activity was best identified using
KCT and should be specifically confirmed by PNP (Table
1).
In direct determination of APAs using the solid-phase
ELISA immunoassay method, 8 out of the 25
experimental subjects with RPL (32%) exhibited APA
positivity while only 5 (20%) exhibited APA positivity
when a combination of KCT and PNP tests were used in
order to determine the LA activity. In this situation, the
ACA solid-phase immunoassay seems to be more
sensitive. However, in the control group consisting of 15
healthy women with no clinical or laboratory evidence of
APA positivity, one woman exhibited ACA positivity (7%)
while none exhibited LA activity. This implies that,
although highly sensitive, ACA determination is not
sufficiently specific. From this point of view, the screening
of APAs both with ACAs for sensitivity and LA for
specificity would reinforce the diagnosis.
While, in previous studies, in cases of RPL, fetal losses
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occurred in 88-100% of pregnancies, in this study, a RPL
rate of about 93% was detected both in APA (+) and
(-) patients. Abortions occurring during the first
trimester were the most prevalant in RPL cases (78%).
The incidence of this was 72% in the APA (+) group,
while it was 83% in the APA (-) group. However, it was
detected that abortions occurring during the second
trimester were more common in the APA (+) group
(14%) than the APA (-) group (5%). In only 13% of the
cases, IUMF occurred in the third trimester.
It is noteworthy that missed abortions were more
common (36%) in the APA (+) group than the APA (-)
group (22%). In particular, the missed abortion
prevalence in the second trimester was 11% in the APA
(+) group, while no such case was detected in the APA (+)
group than the APA (-) group (22%). In particular the
missed abortion prevalence in the second trimester was
11% in the APA (+) group, while no such case was
detected in the APA (-) group. Nevertheless, no significant
correlation between APA positivity and RPL rate could be
detected. In addition, no significant difference was
observed between primary and secondary aborters or
between fertile and subfertile groups.
In the experimental group, no positivity was detected
for the indirect Coombs test (ICT), antinuclear antibodies
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(ANAs), anti-DNA antibodies, LE cells or a biologically
false positive serologic test for syphilis (BFP-STS). There
was no decrease in the serum C3 or C4 complement or
thrombocyte levels.
It is not yet clear whether APAs are an
epiphenomenon associated with underlying thrombotic
diathesis or an early marker of a developing autoimmune

disease. Until this question is answered, women with
unexplained RPL should be screened for the presence of
APAs. Since treatment with corticosteroids and antiaggregants, high-dose intravenous immunoglobulins and
plasmapheresis can lead to successful pregnancies (21,
24, 31), it would be wise to monitor closely cases with
APA positivity.
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